BioLumix DMF Submission for Rapid Microbiological System Accepted by FDA

The FDA have accepted a BioLumix Drug Master File (DMF) entitled 'Microbiological Rapid Method for the Detection and Enumeration of Microorganisms in Pharmaceutical Products'.

The DMF provides specific technical and regulatory information to the FDA which allows companies planning to use the BioLumix Rapid Microbiological System to obtain regulatory approvals for prescription drugs.

Dr. Ruth Eden, President of BioLumix said, 'The DMF can be referenced by drug manufacturers, reducing FDA review times and accelerating the regulatory approval process for use of the BioLumix System. In addition, Over the Counter (OTC) products can be tested in conjunction with the BioLumix Validation Package. The BioLumix DMF includes the information the FDA requires to assess alternative microbiological detection systems; such as, information about the technology, its accuracy, specificity, limit of detection, robustness, ruggedness, and equivalence to USP methodology.'

'The FDA actively encourages use of new technologies including rapid microbiology methods (RMM)' stated Dr. David Hussong, FDA's Associate Director for New Drug Microbiology, Office of Pharmaceutical Science, CDER. Newer microbiological methods can improve company's' quality of testing and result in significant financial savings. Such methods can reduce cycle times resulting in a leaner and more responsive supply chain.

'The BioLumix System is extremely easy to operate, with its straightforward, streamlined testing design it offers rapid, accurate results leading to reduced material-holding time for faster product release.' said Kevin LaBrecque, Director of sales and Marketing at BioLumix. He continued, 'It offers simplified single-platform testing for all assays with a 48-hour Automated Certificate of Analysis, while avoiding any product interference.'